Background--Stroke is a leading cause of death in the world. In >80% of strokes, the initial acute phase of ischemic injury is due to the occlusion of a blood vessel resulting in severe focal hypoperfusion, excitotoxicity, and oxidative damage. Interferon-b (IFNb), a cytokine with immunomodulatory properties, was approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis for more than a decade. Its anti-inflammatory properties and well-characterized safety profile suggest that IFNb has therapeutic potential for the treatment of ischemic stroke.
S
troke is a leading cause of death and results in permanent disability in up to 30% of survivors. In >80% of strokes, the initial acute phase of ischemic injury is due to the occlusion of a blood vessel, resulting in severe focal hypoperfusion, excitotoxicity, and oxidative damage. [1] [2] [3] The inflammatory response that characterizes the subacute phase of ischemia is initiated by resident microglia (MG) and peripheral inflammatory cells infiltrating the region surrounding the infarct core and leading to secondary neurodegeneration. 4 The initiation of cerebral ischemia is associated with blood-brain barrier (BBB) breakdown, extravasation of plasma protein and bioactive phospholipids, rapid activation of resident MG resulting in migration to the ischemic site, and the release of endogenous nitric oxide, proinflammatory cytokines such as tumor necrosis factor (TNF)a and interleukin (IL)-1b, and chemokines such as CCL2 and CCL3. 4, 5 TNFa induces the upregulation of adhesion molecules on cerebral endothelial cells and, in conjunction with CCL3 and CXCL3, promotes the adhesion and directed transmigration of blood-borne leukocytes. This results in infiltration of peripheral immune cells including neutrophils, monocytes/macrophages, and T cells into the infarcted tissue. Invading monocytes/macrophages were detected in the ischemic brain as early as day 1, reaching a peak on day 3. The numbers of neutrophils and T lymphocytes including CD4 + T cells, natural killer T cells, and cd T cells were increased on day 3 and declined on day 7 postinjury. 1, 6 Current clinical therapies using thrombolytic agents are limited by temporal restrictions and do not prevent the secondary, inflammation-related central nervous system (CNS) damage. Therefore, the development of new antiinflammatory therapies in ischemic stroke is necessary and urgent. Interferon-b (IFNb), a cytokine with immunomodulatory properties, was approved by US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis for more than a decade. 7, 8 Its anti-inflammatory properties, [9] [10] [11] [12] [13] and well-characterized safety profile suggest that IFNb has therapeutic potential for the treatment of ischemic stroke. In this study, we evaluated the therapeutic effect of IFNb in the mouse model of transient middle cerebral artery occlusion/reperfusion (MCAO/R). Our results show that IFNb not only reduced infarct size in ischemic brains but also lessened neurological deficits in ischemic stroke animals. Moreover, the reduction of brain infarct in the IFNb-treated mice was associated with decreased infiltration of monocytes/macrophages, neutrophils, cd T cells, and CD4 + T cells. Further investigation of molecular mechanisms revealed that IFNb treatment inhibited the production of inflammatory mediators, suppressed the expression of adhesion molecules, and repressed the activation of MG in the ischemic brain. Thus, our results suggest that IFNb has a protective effect in ischemic stroke through its antiinflammatory properties.
Materials and Methods
Mice C57BL/6 wild-type mice were obtained from Jackson Laboratories. Ifnar1 tm1Agt /Mmjax (Ifnar1 À/À mice) were purchased from Mutant Mouse Regional Resources Center. All mice were kept and bred in the animal facility of Indiana University School of Medicine-Fort Wayne. All animal procedures in this study were conducted in strict compliance with the National Institutes of Health "Guide for the Care and Use of Laboratory Animals" and approved by Purdue Animal Care and Use Committee.
Reagents
Lipopolysaccharide (LPS; Escherichia coli O55:B5) and triphenyltetrazolium chloride (TTC) were purchased from SigmaAldrich. IFNb was purchased from PBL Interferon Source. Recombinant murine granulocyte-macrophage colony-stimulating factor and TNFa were purchased from Peprotech Inc. 
Mouse Focal Brain Ischemia Model
Male mice, aged 8 to 12 weeks and weighing 20 to 30 g, were subjected to MCAO/R for induction of focal brain ischemia. Briefly, the mice were initially anesthetized with 2% and maintained on 1.5% isoflurane in a mixture of 70% air and 30% O 2 with the use of a vaporizer. Body temperature was maintained at %37°C with a warming lamp and heating pad. Cerebral blood flow was measured before, during, and after ischemia by using laser Doppler flowmetry at the parietal bone (2 mm posterior and 3 mm lateral from bregma). Each mouse's resting CBF value was taken as the baseline value, and changes in cerebral blood flow after the induction of brain ischemia were expressed as percentages of the resting value. The right common carotid artery and the right external carotid artery were exposed through a midline neck incision. The external carotid artery was dissected distally, ligated, and coagulated along with the terminal lingual and maxillary artery branches. A minimal incision was made in the external carotid artery stump, with iridectomy scissors. After the incision, occlusion of the middle cerebral artery was performed by using a siliconcoated 6-0 nylon monofilament (Doccol Corp; 0.23 mm). The distance from the suture tip to the right common carotid artery bifurcation was %9 mm. During right middle cerebral artery occlusion, a reduction in cerebral blood flow of >60% was confirmed with laser Doppler flowmetry. Forty minutes after MCAO, the filament was withdrawn to allow blood flow reperfusion. After surgery, mice recovered in cages, where the temperature was kept at 34°C for 1 hour. For IFNb treatment, 10 000 U of recombinant murine IFNb suspended in 100 lL of PBS were administered via intravenous injection to MCAO/R mice. The concentration of IFNb used in this study was based on the previous study established in experimental autoimmune encephalomyelitis models.
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Infarct Volume Measurements
Forty-eight hours after reperfusion, the mice were sacrificed and their brains were removed. Next, 2-mm coronal slices were obtained with use of a rodent brain matrix. The sections were stained with 1% TTC for 10 minutes at 37°C for measurements of infarct volume. Infarction volume was calculated according to Swanson and colleagues to compensate for brain swelling in the ischemic hemisphere 17 and analyzed by using ImageJ (National Institutes of Health).
Neurological Assessment
Neurological function was evaluated by using a 6-point score as previously described 18 and performed at 48 hours after
reperfusion. An expanded 6-point scale is used (0, normal; score 1, mild circling behavior with or without inconsistent rotation when picked up by the tail, <50% attempts to rotate to the contralateral side; score 2, mild consistent circling, >50% attempts to rotate to contralateral side; score 3, consistent strong and immediate circling, the mouse holds a rotation position for more than 1 to 2 seconds, with its nose almost reaching its tail; score 4, severe rotation progressing into barreling, loss of walking, or righting reflex; and score 5, comatose or moribund).
Mononuclear Cell Isolation and FluorescenceActivated Cell Sorter Analysis
Mice were perfused with ice-cold PBS; brains were freed from meninges; and the olfactory bulb and cerebellum were discarded. The harvested brains were separated into hemispheres. The brain was homogenized with 19 Hanks balanced saline solution buffer and filtered through a 40-lm nylon cell strainer. After centrifugation, cells were resuspended in 10 mL of 30% Percoll and underlayered with 5 mL of 70% Percoll. The samples were then centrifuged at room temperature for 25 minutes at 1000g. The cells at the 30:70 interface were isolated, washed, and stained with anti-CD45, anti-CD11b, and anti-Ly6G, followed by fluorescence-activated cell sorter (FACS) analysis of 20 000 counts per sample. For CD4 + T-cell and cd T-cell analysis, the cells collected from the 30:70 interface were stained with anti-CD3, anti-CD4, and anti-TCRcd, followed by FACS analysis.
Real-Time Reverse Transcription-Polymerase Chain Reaction
Expression of different genes was detected by quantitative polymerase chain reaction as previous described. 19 The sequences of primers are as following: E-selectin: 
Immunohistochemistry
Mice were transcardiacally perfused with PBS and brains were extracted. Coronal brain blocks (2 mm) were cut, postfixed in 4% paraformaldehyde, and cryoprotected in 6% followed by 30% sucrose-PBS. Brain blocks were subsequently embedded in optimal cutting temperature compound and frozen with isopentane cooled by liquid nitrogen. Serial 15-lm frozen sections were cut in a cryostat, mounted on superfrost plus slides, and stored at À20°C until staining. After washing with PBS, slides were permeabilized with 0.5% Triton X-100/PBS for 30 minutes and then incubated with blocking solution (0.25% Triton X-100/PBS, 3% normal donkey serum in PBS) for 1 hour at room temperature. The primary antibody (rabbit anti-Iba1, 1:800; Wako) was added on slides for 2-hour incubation at room temperature. Slides were washed with PBS and incubated with fluorescent secondary antibody (donkey anti-rabbit IgG, 1:400 Alexa Fluor 488; Invitrogen) for 1 hour at room temperature. After washing with PBS, slides were mounted and coverslipped with ProLong Gold anti-fade mountant with DAPI (Invitrogen). Brain regions of interest were defined in relation to anatomical landmarks by using the Franklin and Paxinos Mouse Brain in Stereotaxic Guidance. The Nuance FX multispectral imaging system and Nuance software (PerkinElmer) were used for image collection and analysis. Each stained section was processed under identical gain and laser power setting. Two or 3 different sections from each mouse at the bregma 0.98 to 0.86 mm were stained and analyzed (n=6 mice in the vehicle-and IFNb-treated groups).
Activation of MG was evaluated on the basis of Iba1 intensity exceeding the set threshold and of cellular morphology. Image of single-cell morphology was acquired by using the Fluoview FV10i confocal microscope (Olympus) and analyzed with the use of ImageJ.
Immunocytochemistry
MG were fixed in 2% paraformaldehyde for 15 minutes at room temperature. After being washed with PBS, cells were permeabilized with 0.3% Triton X-100/PBS for 10 minutes and then blocked in 3% normal donkey serum for 30 minutes at room temperature. Cells were incubated with primary antibody (rabbit anti-Iba1, 1:800) for 1 hour at room temperature. After being washed with PBS, cells were incubated with fluorescent secondary antibody (donkey anti-rabbit, 1:400 Alexa Fluor 488) for 1 hour at room temperature. After being washed with PBS, cells were coverslipped with ProLong Gold antifade mountant with DAPI (Invitrogen). Confocal images were acquired by using Fluoview FV10i confocal microscope (Olympus) and analyzed by using ImageJ.
Statistical Analysis
Results are given as meanAESEM. Comparisons between 2 groups were done by using the paired t test, whereas comparisons between multiple groups were done by using 1-way ANOVA followed by Bonferroni post hoc test. For in vivo study with the groups containing ≥7 mice, a Shapiro-Wilk normality test was performed to ensure a normal distribution of the data. For neurological scores, comparisons between 2 groups were calculated with use of the v 2 test of proportions.
For quantitative cell counts of activated MG and measurements of MG soma size in the immunohistochemistry brain samples, comparisons between multiple groups were calculated with the use of Kruskal-Wallis test followed by Dunn post hoc test. Statistical significance was determined with P values <0.05.
Results
IFNb Confers a Protective Effect Against Ischemic Stroke
In this study, we used the mouse MCAO/R model. Physiological parameters for the MCAO/R mice are listed in Table. All mice had similar body temperatures and blood oxygen levels during surgery, and a blood flow drop of >60% between the initial reading and after suture insertion. We first evaluated whether pretreatment with IFNb would offer a protective effect in ischemic stroke. Mice were administered IFNb or vehicle 3 hours before the induction of MCAO/R. Forty-eight hours after reperfusion, infarct volumes were assessed by using TTC staining. Pretreatment with IFNb significantly reduced the infarct volume (5.4AE0.8 IFNb versus 15.2AE1.9 vehicle; Figure 1A and 1B). Lower neurological scores were also observed in IFNb-treated mice (1.2AE0.2 IFNb versus 2.1AE0.3 vehicle; Figure 1C ). We then evaluated the therapeutic effect of IFNb treatment in ischemic stroke. IFNb was administrated to MCAO/R mice 3 hours after reperfusion, and the ischemic brain infarction was accessed by using TTC at 48 hours postreperfusion. Similar to the results of IFNb pretreatment, IFNb posttreatment reduced infarct volumes (7.3AE0.8 IFNb versus 15.9AE1.2 vehicle; Figure 1D and 1E) as well as the neurological score (1.4AE0.2 IFNb versus 2.2AE0.3 vehicle; Figure 1F ). The protective effect of IFNb in ischemic stroke is mediated through type I IFN receptor because IFNb failed to reduce infarct volume in Ifnar1 À/À MCAO/R mice compared with vehicle-treated controls ( Figure 1G and 1H). Altogether, our results demonstrated IFNb attenuated ischemic brain infarct and lessened ischemia-induced neurological deficits, suggesting its therapeutic potential for ischemic brain injury.
IFNb Suppresses Inflammation in Ischemic Brains
Ischemia-induced CNS inflammation exerts a fundamental role in stroke pathophysiology and promotes infarct formation in the R) mice are protected from cerebral ischemic injury. C57BL/6 mice (n=10/group) intravenously treated with vehicle or IFNb were subjected to MCAO/R 3 hours later. A, Forty-eight hours after MCAO/R, mice were sacrificed, and ischemic brains were harvested and sliced (2 mm), followed by TTC staining. B, The infarct size of ischemic brains of vehicleand IFNb-pretreated mice was measured. C, Neurological scores of vehicle-and IFNbtreated MCAO/R mice were evaluated. C57BL/6 mice (n=15/group) subjected to MCAO/R were treated with vehicle or IFNb 3 hours after reperfusion. D, Ischemic brains of vehicleand IFNb-treated MCAO/R mice were subjected to TTC staining, and 5 representative TTCstained samples are shown. E and F, The infarct volume was measured and the neurological scores were determined. Type I IFN receptor-deficient (Ifnar1
) mice (n=8/group) were subjected to MCAO/R and treated with vehicle or IFNb 3 hours after reperfusion. At 48 hours later, the mice were sacrificed, and brains were sliced (2 mm), followed by TTC staining. (Figure 1 ), we investigated whether IFNb inhibits the production of inflammatory cytokines in the ischemic brains at an early phase (24 hours post injury). We collected ischemic brains from MCAO/R mice 24 hours after reperfusion and extracted RNA followed by quantitative PCR analysis for inflammatory cytokine expression. Our results show that inflammatory cytokines, including IL-1b, IL-6, IL-23p19, and TNFa, were upregulated in the ipsilateral hemispheres of vehicle-treated MCAO/R mice and that IFNb treatment significantly reduced proinflammatory cytokine expression (Figure 2) . Thus, our results suggest that IFNb-mediated reduction of inflammatory cytokine expression in the ischemic brain might contribute to its protective effects in ischemic stroke.
IFNb Suppresses MG Activation in Ischemic Brains
In response to ischemic injury, rapidly activated MG are the major source of inflammatory mediators that cause cytotoxic effects in the ischemic brain. 22, 23 Because the upregulation of inflammatory cytokines in the ischemic brain was inhibited by IFNb (Figure 2 ), we speculated that IFNb might suppress MG activation. Brain slices were prepared from 24-hour ischemic brains followed by Iba1 staining. Cerebral ischemia significantly increased Iba1 expression in the cortex of ipsilateral, but not contralateral hemispheres ( Figure 3A, top) . When comparing MG activation in the ipsilateral hemispheres of vehicle-and IFNb-treated MCAO/R mice, IFNb treatment markedly suppressed Iba1 expression ( Figure 3A, right) . In addition, confocal images showed a round and amoeboid morphology with shorter processes and enlarged soma in vehicle controls, suggestive of activated MG, whereas MG from IFNb-treated animals displayed ramified morphology with long branching processes and smaller soma, indicative of a resting phenotype ( Figure 3A , insets). Quantitative analysis of MG activation revealed a significant reduction in Iba1 + cell numbers ( Figure 3B, top) as well as soma size ( Figure 3B , bottom) for IFNb-treated MCAO/R mice. 
Cont.
Ipsi. Cont. + T and cd T cells in the ischemic brain. A, C57BL/6 mice (n=8/group) subjected to middle cerebral artery occlusion/reperfusion (MCAO/R) were treated with either vehicle or IFNb 3 hours after reperfusion. Ninety-six hours later, mice were sacrificed, and ischemic brains were harvested and sliced (2 mm), followed by TTC staining. B, The infarct volume of ischemic brains was measured. ***P<0.001 by paired t test. C, Mononuclear cells were isolated from the contralateral and ipsilateral hemispheres of vehicle-and IFNb-treated mice as well as sham control brains. Cells were stained with antibodies against CD3, CD4, and The inhibitory effect of IFNb on MG activation was further confirmed in primary MG in vitro. Cells were treated with LPS in the presence or absence of IFNb for 24 hours followed by Iba1 staining. MG treated with LPS had increased Iba1 expression and changed morphology from ramified to the amoeboid phenotype. IFNb suppressed LPSinduced Iba1 expression and preserved the ramified phenotype similar to the phenotype of resting MG (MED; Figure 3C ). In addition, IFNb inhibited LPS-induced IL-1b and IL-12p40 expression ( Figure 3D ). Taken together, our results demonstrate that IFNb suppressed ischemia-induced MG activation in vivo and LPS-induced MG activation in vitro.
Ipsi. Sham
IFNb Diminishes Peripheral Immune Cell Infiltration Into the Ischemic Brain
Cerebral ischemia followed by reperfusion promotes CNS infiltration of peripheral immune cells including neutrophils, monocytes/macrophages, and T cells, leading to secondary brain injury characterized by enlarged brain infarction. 22, 24 To investigate whether IFNb affects inflammatory cell infiltration, we characterized infiltrating cell populations in the ischemic brains of vehicle-and IFNb-treated MCAO/R mice at 48 hours after reperfusion. We observed a significant increase in cell numbers of CD45 25, 26 In line with previous study, 26 we found increased numbers of CD4 + T and cd T cells in the ischemic brains and enlarged infarct size on day 4 post injury. More importantly, IFNb treatment diminished both CD4 + T-and cd T-cell numbers ( Figure 5C and 5D) and attenuated infarct size ( Figure 5A and 5B). Taken together, our results demonstrate that IFNb treatment suppressed the infiltration of monocytes/macrophages, neutrophils, and CD4 + T and cd T cells, suggesting that inhibition of CNS infiltration of inflammatory cells represents one of the mechanisms for the protective effect of IFNb in ischemic stroke.
IFNb Inhibits Adhesion Molecule Expression in the Ischemic Brain
The influx of inflammatory cells into ischemic brains is facilitated by adhesion molecules expressed on the surface of brain endothelial cells. E-selectin, P-selectin, ICAM-1, and vascular cell adhesion molecule (VCAM)-1 were reported to be upregulated in brain endothelial cells within hours of reperfusion in the MCAO/R model. 27, 28 Our results also demonstrate a marked increase in ICAM-1 and E-selectin in the ipsilateral hemispheres at 24 hours post ischemia (Figure 6A) . Further comparison of ICAM-1 and E-selectin expression in IFNb-and vehicle-treated MCAO/R mice revealed that IFNb abolished ischemia-induced upregulation of ICAM-1 and E-selectin in the ipsilateral hemispheres ( Figure 6A ). Although it was previously reported that the expression of VCAM-1 was increased in ischemic brains, we did not observe an increase of VCAM-1 expression in ipsilateral compared with contralateral hemispheres of stroke mice, and IFNb treatment did not alter VCAM-1 expression in the ischemic brain (results not shown). The effect of IFNb on the expression of adhesion molecules was also studied in the brain endothelial cell line bEnd.3. bEnd.3 cells were activated with TNFa in the absence or presence of IFNb, and the expression of adhesion molecules was measured at mRNA and protein levels. TNFa upregulated ICAM-1 and E-selectin expression at both mRNA and protein level and IFNb inhibited TNFa-induced ICAM-1 and E-selectin upregulation ( Figure 6B and 6C). In addition, IFNb reduced TNFa-induced surface Pselectin expression ( Figure 6D ). Although TNFa upregulated VCAM-1, IFNb did not affect VCAM-1 expression (data not shown). Altogether, our results demonstrate that IFNb inhibited the upregulation of adhesion molecules in the ischemic brain and in brain endothelial cells.
IFNb Suppresses Chemokine and Matrix Metallopeptidase 9 Production in Ischemic Brains
Chemokines produced in the ischemic brain facilitate the recruitment of peripheral immune cells to the site of injury. Chemokines such as CCL2/3, essential for monocyte/ macrophage recruitment, and CXCL3, essential for neutrophils recruitment, are highly induced in the ischemic brain. [29] [30] [31] In addition, matrix metallopeptidase (MMP)-9 released during ischemic injury compromises BBB integrity and facilitates CNS infiltration of inflammatory immune cells. 32 To investigate whether IFNb regulates chemokines and MMP-9 production in the ischemic brain, we compared the expression of CCL3, CXCL3, and MMP-9 in vehicle-and IFNb-treated MCAO/R mice. The expression of CCL3, CXCL3, and MMP-9 was dramatically increased in the ipsilateral but not contralateral hemispheres ( Figure 7A ). Importantly, IFNb treatment impaired ischemia-induced CCL3, CXCL3, and MMP-9 expression in the ischemic brain ( Figure 7A ). We further investigated the effect of IFNb on chemokines and MMP-9 production in MG, major producers of these inflammatory mediators during brain ischemia. Similar to the in vivo results, IFNb reduced CCL3, CXCL3, and MMP-9 expression in LPS-activated MG ( Figure 7B and 7C). 
Discussion
The effect of IFNb in cerebral ischemia, reported in a rather limited number of publications, is still controversial. In a study of transient focal ischemia in rat, IFNb failed to show a protective effect, 33 whereas 3 other studies reported beneficial effects on systemic or intracerebroventricular administration of IFNb in a rabbit model of thromboembolic cerebral ischemia 34 and in rat and mouse models of transient MCAO/ R. 35, 36 The only mechanism identified to date is the inhibitory effect of IFNb on MMP-9 production resulting in reduced CNS infiltration of monocytes and neutrophils. 36 In this study, our aim was to better understand the protective effects of IFNb in ischemic stroke, with the ultimate goal of developing an IFNbbased therapeutic strategy for the treatment of ischemic stroke.
We used the mouse model of MCAO/R to study the effect of IFNb treatment in cerebral ischemia. IFNb was administered systemically either before or after MCAO/R and the effect was evaluated on days 2 and 4 post ischemia. IFNb administration 3 hours before MCAO/R resulted in a %64% reduction in infarct volume. IFNb administration 3 hours post ischemia, which is the therapeutically relevant regimen, still reduced infarct volume on day 2 by %54%. Chemokines, in addition to adhesion molecules, are required for recruiting leukocytes. During ischemic injury, chemokines such as CCL2/3 and CXCL3 are released and promotes leukocyte recruitment. [40] [41] [42] [43] [44] In line with previous findings, our results show that CCL3 and CXCL3 are upregulated in the ischemic brain. Moreover, we show for the first time that IFNb inhibits CCL3 and CXCL3 expression in the ischemic brain. CCL3 and CXCL3 function in the recruitment of monocytes/macrophages and neutrophils, respectively, and the IFNb-induced decrease in CCL3 and CXCL3 expression correlates with reduced infiltration of monocytes/macrophages and neutrophils in the ischemic brain of IFNb-treated MCAO/R mice.
The study by Shichita and colleagues demonstrated that IL-17-producing cd T cells play a pivotal role in ischemic stroke pathogenesis. 26 Although IL-17-deficient mice developed brain infarct at the early phase (day 1), the infarct did not enlarge during the delayed phase (day 4) of ischemic stroke, suggesting that IL-17 plays a pathogenic role during the delayed phase. Moreover, the study also demonstrated that cd T cells activated by IL-1b and IL-23 were the major producers of IL-17 during ischemic stroke and were responsible for the exacerbation of brain injury during the delayed phase of ischemia. Our results show that IFNb attenuates brain infarct size at the delayed phase (day 4), suggesting that IFNb might suppress cd T-cell infiltration. We observed a large increase in cd T-cell numbers in the ischemic brain on day 4. More importantly, IFNb significantly decreased the number of cd T cells in the ischemic brain. Although we did not specifically measure IL-17 production by CNS-infiltrating cd T cells, the expression of IL-1b and IL-23 in the ischemic brain was inhibited by IFNb, which would ultimately result in decreased recruitment to and activation of IL-17-producting cd T cells in the ischemic brain. To the best of our knowledge, this is the first report that one of the mechanisms for the protective effect of IFNb in ischemic stroke involves the reduction in cd T-cell infiltration during brain ischemia. In summary, here we demonstrate that IFNb reduces ischemic brain infarct through its anti-inflammatory effects. Several molecular mechanisms were identified in our current study. First, IFNb reduces CNS infiltration of inflammatory cells, including monocytes/macrophages, neutrophils, CD4 + T cells, and cd T cells. Second, IFNb suppressed the expression of inflammatory cytokines, chemokines, MMP-9, and adhesion molecules in the ischemic brain. Finally, IFNb inhibited ischemia-induced MG activation. Current American Heart Association Stroke Council guidelines for the treatment of patients with acute ischemic stroke include administration of tissue plasminogen activator intravenously within 3 hours of the ischemic attack. Although this treatment reduces neurological deficits and improves functional outcomes, 45 it also increases reperfusion damage. This is primarily due to the recruitment of inflammatory immune cells to the CNS through the combined activity of MMPs, chemokines, and inflammatory cytokines that affect both the BBB and the peripheral immune cells. 46, 47 Therefore, through its multiple effects, including inhibition of proinflammatory cytokines, chemokines, and MMP-9, reduction in inflammatory cell recruitment to the CNS, and inhibition of microglia activation, IFNb is a potential therapeutic agent targeting the reperfusion damage subsequent to the treatment with tissue plasminogen activator.
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